Four centrosome-related genes to predict the prognosis and drug sensitivity of patients with colon cancer.

Background: As the primary microtubule organizing center in animal cells, centrosome abnormalities are involved in human colon cancer.

Aim: To explore the role of centrosome-related genes (CRGs) in colon cancer.

Methods: CRGs were collected from public databases. Consensus clustering analysis was performed to separate the Cancer Genome Atlas cohort. Univariate Cox and least absolute shrinkage selection operator regression analyses were performed to identify candidate prognostic CRGs and construct a centrosome-related signature (CRS) to score colon cancer patients. A nomogram was developed to evaluate the CRS risk in colon cancer patients. An integrated bioinformatics analysis was conducted to explore the correlation between the CRS and tumor immune microenvironment and response to immunotherapy, chemotherapy, and targeted therapy. Single-cell transcriptome analysis was conducted to examine the immune cell landscape of core prognostic genes.

Results: A total of 726 CRGs were collected from public databases. A CRS was constructed, which consisted of the following four genes: , , , and . Colon cancer patients with a high-risk signature had poor survival. Patients with a high-risk signature exhibited decreased levels of plasma cells and activated memory CD4+ T cells. Regarding treatment response, patients with a high-risk signature were resistant to immunotherapy, chemotherapy, and targeted therapy. expression was relatively high in endothelial cells and fibroblasts. expression was high in endothelial cells, fibroblasts, and malignant cells.

Conclusion: We constructed a centrosome-related prognostic signature that can accurately predict the prognosis of colon cancer patients, contributing to the development of individualized treatment for colon cancer.